

MicroPort Scientific Corporation

2023 Interim Results

August 2023

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words

"anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.



Contents


1 Company Highlights

2 Business Review

3 Financial Review

4 Outlook

5 Appendix Financial Statements



Partnerships with global leading KOLs and MedTech firms

Unswervingly invested in R&D for 25 years


Global leading medical devices company

Uncompromising in quality and relentless pursuit of excellence

Industry leading commercialization capabilities

**Building a super-conglomerate of people centric enterprises of
EMERGING MEDICAL TECHNOLOGIES**

1H23 Highlights



Newly obtained



Global Strategic Triangle








Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix Financial Statements


Business highlights




Product pipeline



Non-China business




China business




Business overview


1H23 revenue \$104.2mn, up 7.7% YOY, strong revenue growth disrupted by supply chain issue since March, significant recovery seen in July;
Accomplished **~19% growth in volume** as prior year, becoming the highest sales volume ever achieved, despite supply challenges globally;
Knee sales **up 16% YOY**, thanks to the growing popularity of Medial Pivot design, as well as **synergy with SkyWalker™**;
Completed **FDA 510 (k) submission** for Evolution® Hinge knee joint system and Procotyl® P Acetabular Cup;
Global manufacturing collaboration in progress, multi-projects in execution.

CRM business





Business highlights



1H23 revenue \$40.5mn, up 46.4% YOY, with significant enhancement seen in profitability;

Market access: newly entered **200+** hospitals, total coverage reached **2,800+** **100+** hospitals, covered **~700** hospitals in **200+** lower-tier;

Product sales: thanks to continuous market penetration, maintained strong sales growth of Tubridge®; NUMEN® & Bridge® & U-track® gained fast-growing market share; rapid market entry of Neurohawk® & Diveer®;

Registration: 4 NMPA approvals & 3 products submitted for NMPA, further enhanced AIS product portfolio, create integrated and diversified neurovascular disease solution with 17 commercialized products.



International business generated revenue of **\$2.1mn**, up 27.3% YOY;

Four products successfully commercialized in 12 countries/ regions, covering half of the countries ranking top 10 worldwide by volume;


NUMEN® completed 1st commercial implantations in **5** countries, newly approved in 4 countries;

U-track® completed 1st batch of commercial use in Brazil;

Tubridge® & Fastrack® obtained market approval in Argentina.

	Product	Pre-clinical	Clinical	Registration
Hemorrhagic Stroke	Tubridge Plus® Flow-diverting Stent			Completed enrollment of registration trial
	Comaneci® Embolization Assist Device*			CE marked & FDA cleared FDA Breakthrough Device Designation Design validation stage
	Rebridge® Intracranial Visualized Stent			Design validation stage
	Liquid Embolic Agent			Design validation stage
ICAD	Intracranial Drug-Coated Balloon Catheter System			Design validation stage
Acute Ischemic Stroke	Tigertriever® Revascularization Device*			✓ NMPA approved & CE marked & FDA cleared
	W-track® Intracranial Aspiration Catheter			✓ NMPA approved
	Balloon Guide Catheter			Submitted for NMPA review
	Neurohawk® Stent Thrombectomy Device 2			Submitted for NMPA review
	Tigertriever® 13 Revascularization Device*			FDA cleared Design validation stage
Accessories	Q-track® Microcatheter			✓ NMPA approved
	Veronwire™ Neurovascular Guide Wire			✓ NMPA approved
	Distal Protection Device			Submitted for NMPA review

Business highlights



1H23 revenue \$24.1mn, up 38.4% YOY, implantations **up ~46% YOY**, market share rises in top centers, penetrate continues in primary market; Gross profit margin maintain improving trend, up **2 ppts** as compared with 1H22, significantly improvement also seen in operation efficiency; Successfully entered **~70** centers, hospital coverage reached **500+**, single-center implantation increased by **8 ppts**;

AccuSniper **NMPA approval**;
Smoothly progressing FIM study of self-developed TMVR system, **one-year follow-up** shows significant MR reduction with no recurrence, notable improvement of cardiac function, and quality of life;
VitaFlow® III completed design freeze, expected NMPA submission in Q4.



Strong revenue growth out of China, **up 243.1% YOY**, leverage on strong sales channel of Cardiovascular business, TAVI procurement increased rapidly since launched in South America;
Successfully entered **60+** hospitals overseas, conducted **100+** commercial implantations accumulatively;

registration, expected to be the **1st Chinese TAVI product** with CE mark

	Product	Pre-clinical	Clinical	Registration
TAVI	VitaFlow Liberty®			Approaching CE registration
	VitaFlow® III			Approaching Design freeze
	VitaFlow® Novo Generation			Design stage
	VitaFlow® Balloon Expandable			Animal studies
Access	AccuSniper Double Layer Balloon Catheter			✓ NMPA approved
	Expandable Sheath			Design stage
TMV	Self-developed replacement product			Progressing FIM studies
	Self-developed edge to edge repair product			Animal studies
	AltaValve - replacement product			Approaching EFS Completion
	- repair product			Progressing EFS
TTV	Self-developed replacement product			Design Stage
	Self-developed edge to edge repair product			Design stage
	Replacement product - partnership with 4C			Design stage

Toumai® Laparoscopic
Surgical Robot ®

✓ **Obtained NMPA**
CE marking in progress

Toumai® 2nd Generation

Submitted for NMPA review

Toumai® Single-arm
Laparoscopic Surgical Robot

Started enrollment of registrational trial

Skywalker™
Orthopedic Surgical Robot

~~p(m)De~~ **Obtained NMPA**





Business overview

Provide **systematic life support solutions for acute critical cases**;
1H23 revenue \$3.1mn, up 39.4% YOY, thanks to rapid overseas sales of oxygenators, smoothly promoting hospital entry of Vitasprings femoral cannula series obtained NMPA approval, become the 1st China-developed TPU Femoral Cannula to go to market.



Product overview

19

received









received

Flagship **MOBYBOX ECMO System**

1st fully integrated ECLS system to provide both blood flow and gas management in a single device, obtained CE mark under MDR regulation; Leverage on diversified portable design, aiming to forge **movable critical-care unit** focusing on pre-hospital emergency care.



Globalization

	Product	Pre-clinical	Clinical	Registration
Emergency transport system	Hemovent ¹ MOBYBOX [®] ECMO 	✓ Obtained CE mark		
	Hemovent ¹ MOBYO [™] ECMO Oxygenator	✓ Obtained CE mark		
	Hemovent ¹ WATCHA Blood Oxygen Saturation Monitoring Sensor	✓ Obtained CE mark		
ECMO	Centrifugal ECMO system		Approaching Animal studies	
	Double lumen cannula		Approaching Animal studies	
	Transseptal cannula		Design stage	
CPB	Cannula series	✓ Obtained NMPA approval		
	FILAVENT Femoral Cannula series	✓ Obtained NMPA approval & CE mark		
	MOBYO [™] ECMO Oxygenator		Animal studies	
Congenital heart diseases	Atrial Septal Defect Occluder 	✓ Obtained NMPA approval		
	Patent Ductus Arteriosus Occluder 	✓ Obtained NMPA approval		
	Ventricular Septal Defect Occluder 	✓ Obtained NMPA approval		
	Occluder delivery system	✓ Obtained NMPA approval		
Others	Patient monitoring system	Data processing platform	ICU management	Heart failure
				In-hospital transport system

 Product admitted in NMPA Green Path

Business highlight

Provide **total precise interventional imaging solution**, multifaceted coverage including panvascular (cardiovascular, neurovascular, and peripheral vascular), structural heart/EP, metabolism and etc.

1H23 revenue up 298.0% YOY, maintained sales growth of **1st** fully sealed purge-

Processed 1st installation of Soul-Man DSA System

ArgusClarity **Singapore;**

Self-developed IVUS imaging system & accompanying disposable catheter commenced type examination.

	Product	Indication	Pre-clinical	Clinical	Registration
OCT	Insight-100 ArgusClarity	PCI	✓ Obtained NMPA approval	→	CE
	Insight-100 1350 NOPURGE (OCT catheter)	PCI	✓ Obtained NMPA approval	→	
	Insight-100h High Speed OCT	PCI	✓ Obtained NMPA approval	→	
	High Resolution OCT	PCI		Type testing stage	
	Peripheral/Intracranial OCT	Panvascular			
DSA	Soul-Man DSA System	Interventional	✓ Obtained NMPA approval	→	
IVUS	Coronary Artery IVUS	PCI		Type testing stage	
	Peripheral/Intracranial IVUS	Panvascular	→		
	IVUS-ICE	SHD	→		
Multi-module interventional	OCT+IVUS	PCI		Prototype development stage	
	OCT+IVUS+FFR	PCI	→		
MRI	Imported MRI System	Prostate biopsy	✓ Obtained FDA approval	→	
	Chinese MRI System	Prostate biopsy	→		

Product admitted in NMPA Green Path



Business highlights

Provide innovative total solutions in endoscope and disposal devices to **urological, gastrointestinal, gynaecological & respiratory** diseases; **1H23 revenue up 190.0% YOY**, formed total-solution for Urinary Calculus **20 NMPA certificates & 3 CE marks** obtained accumulatively; Milestone progress obtained under the development of endoscopic imaging pipeline in digestive endoscope; Closed strategic financing with RMB 140mn raised.



R&D progress

30+ in pipeline

1 Products obtained

Key product 1st in China, 2nd globally

urethral lift system

Green Path product, Prostatic



Globalization

6 successfully commercialized in 4 countries/ regions

3 obtained CE mark in 2023

	Product	Indication	Pre-clinical	Clinical	Registration
Single-use endoscope	Single-use digital ureteroscope catheter	Urology	✓	Obtained NMPA approval	Progressing registration trial
	Single-use digital choledochoscope catheter	Gastroenterology	✓	Obtained NMPA approval	Progressing registration trial
	7 other candidates covering urological, gastrointestinal, gynecological and respiratory indications				
Reusable endoscope	3 candidates covering gastrointestinal and respiratory indications				
Passive consumables	Nephrostomy balloon dilation catheter		✓	Obtained NMPA approval	Progressing registration trial
	Single-use endoscopic retrieval basket (3 claws)		✓	Obtained NMPA & CE approval	Progressing registration trial
	Ureteral access sheath		✓	Obtained NMPA approval	Progressing registration trial
	Single-use urinary track guidewire	Urology	✓	Obtained NMPA & CE approval	Progressing registration trial
	Ureter balloon dilation catheter		✓	Obtained NMPA & CE approval	Progressing registration trial
	Prostatic urethral lift system		✓	Progressing registration trial	Progressing registration trial
	Hybrid zebra guidewire				Progressing registration trial
Energy-based	Ultrathin basket			Progressing registration trial	Progressing registration trial
	Ruyi	Gastroenterology	✓	Obtained NMPA approval	Progressing registration trial
	6 other candidates covering gastrointestinal and urological indications				
	5 candidates covering general, gynecological and gastrointestinal indications				
Neuro modulation	3 candidates covering urological and respiratory indications				

Product admitted in NMPA Green Path

Business highlights


- ◆ 1H23 revenue increased by **16.6% YOY**, net profit up **44.6% YOY**
- ◆ 3D navigation cases up **50%+ YOY**, maintained **TOP 1** Chinese player with **40,000+** 3D cases performed accumulatively
- ◆ Total hospital coverage reached **900+**, 3D products covered **700+** hospitals, TrueForce® entered **100+** hospitals after successfully launched in February 2023
- ◆ **Green Path** products, IceMagic® Cryoablation System & Catheter obtained **NMPA** approval, become the **1st** China-developed cryoablation system approved

Globalization

- ◆ One of the few global players with **all-around EP solutions**
- ◆ Products entered **31** overseas countries and regions
- ◆ **20 CE** marks & **4 FDA** clearance obtained accumulatively
- ◆ Core product TrueForce® submitted for **CE**

Sports medicine

- ◆ Built integrated product pipeline covering implants, surgical tools, and innovative active devices in sports medicine;
- ◆ Completed **full-coverage** of conventional portfolio, **8** NMPA approvals and **2** FDA clearance obtained in 1H23;
- ◆ Smoothly progressing registration of key innovative projects, Ligatube® received NMPA approval in Aug, become the **1st** China-developed Tunnel-form Rotator Cuff Repair system;
- ◆ Processing bidding for **Galaxy Insight** 4K high-resolution





Contents

1 Company Highlights

2 Business Review


3 Financial Review

4 Outlook

5 Appendix Financial Statements

Revenue

USD: million




Gross profit margin



Operating expenses

USD: million



Sales & marketing expenses

Administrative expenses

R&D expenses

Sales & marketing expenses increased by 15.8%^{YOY}



Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix Financial Statements

Innovative product pipeline fueling long-term growth

Cardio-vascular	Guide Catheter NMPA	Firesorb® Bioresorbable Scaffolds NMPA	Non-slip-element Balloon NMPA	Coronary Covered Stent NMPA	Coronary Rapamycin Drug-coated Balloon NMPA	Coronary Stent Graft System NMPA	Coronary Rotational Atherectomy System NMPA	Intravascular Lithotripsy Balloon NMPA	Firehawk® stent FDA	Pressure Guidewire NMPA
Orthopedics	Classic Profemur® Cemented XM® Femoral Stem FDA		Hinged Knee Joint System FDA	Evolution Tibia Cones FDA		2D-to-3D Imaging Technology FDA	Wrist Joint Prosthesis System NMPA	Procotyl P Acetabular Cup (Dual Mobility/Revision) FDA		
CRM	Pacemaker (MRI) NMPA	BonaFire Passive Lead (MRI) NMPA	ENERGYA/TALENTIA Bluetooth® ICD/CRT-D CE	Left Bundle Branch pacing lead CE	Pulsea Bluetooth® CRT-P CE	Space HP ICD/CRT-D NMPA	Invicta Lead NMPA	Leadless Pacemaker NMPA&CE		
Endo-vascular	Resuscitative Endovascular Balloon NMPA	Vflower® Venous Stent System NMPA	Peripheral PTA Balloon Catheter NMPA	Fibered Embolization Coil NMPA	Vewatch® Vena Cava Filter NMPA	Fishhawk Catheter NMPA	Cratos Branched Aortics Stent Graft System NMPA	Aegis® II Abdominal Aortic Stent Graft System NMPA	TIPS Stent Graft System NMPA	
Neuro-vascular	Comaneci® Embolization Assist Device NMPA	Balloon Protection Guide Catheter NMPA	Neurohawk® Stent Thrombectomy Device 2 NMPA	Tubridge Plus® Flow-diverting Stent NMPA	Tigertriever® 13 Revascularization Device* NMPA	Rebridge® Intracranial Visualized Stent NMPA	Intracranial Drug-Coated Balloon Catheter System NMPA	Liquid Embolic Agent NMPA		
Heart Valve	VitaFlow Liberty® CE	VitaFlow® III NMPA	Novo Generation NMPA	VitaFlow® Balloon Expandable NMPA	Expandable Sheath NMPA	Self-developed TMVR product NMPA	AltaValve TMVR Product NMPA	TMVr Product NMPA	Self-developed edge to edge repair product NMPA	TTV Self-developed replacement product/ Self-developed edge to edge repair/ Trivid
Surgical Robot	R-ONE® Panvascular Surgical Robot NMPA	Skywalker™ Orthopedic Surgical Robot (Hip) NMPA		Toumai® Laparoscopic Surgical Robot CE	Toumai® Single-arm Laparoscopic Surgical Robot NMPA		Trans-bronchial Surgical Robot NMPA	TAVR Surgical Robot NMPA	Spine Surgical Robot NMPA	
Surgical Devices	Arterial Micro-Embolic Filter (new type) NMPA		Double lumen cannula NMPA	MOBYBOX System NMPA	Centrifuge ECMO NMPA		Transseptal cannula NMPA			
Electro-physiology¹	Navigation System V4 NMPA		Flashpoint® Renal Artery Ablation Catheter NMPA	Renal RF Ablation System NMPA		Force-Sensing Pulse Field Ablation Catheter NMPA				



Contents

1 Company Highlights

2 Business Review

3 Financial Review

4 Outlook



USD'000	2023 1H	2022 1H	Var.
Revenue	482,605	404,984	19.2%
Cost of sales	(194,189)	(157,282)	23.5%
Gross profit	288,416	247,702	16.4%
Other net income	17,039	41,356	-58.8%
Research and development costs	(187,334)	(186,430)	0.5%
Distribution cost	(169,800)	(146,610)	15.8%
Administrative expenses	(95,890)	(133,259)	-28.0%
Other operating costs	(12,374)	(8,328)	48.6%
Loss from operations	(159,943)	(185,569)	-13.8%
Finance cost	(37,256)	(46,050)	-19.1%
Gain on deemed disposal of a subsidiary	2,845	-	N/A
Gain on deemed disposal of interest in equity-accounted investees	5,437	1,920	183.2%
Share of losses of equity-accounted investees	(17,258)	(18,141)	-4.9%
Loss before taxation	(206,175)	(247,840)	-16.8%
Income tax	(13,746)	(5,435)	152.9%
Loss for the period	(219,921)	(253,275)	-13.2%
Attributable to: Equity shareholders of the Company	(162,618)	(198,130)	-17.9%

USD'000	30 June 2023	31 Dec 2022	Var.
Non-current assets			
Investment properties	6,315	6,579	-4%
Other property, plant and equipment	969,558	993,014	-2%
Intangible assets	223,215	223,683	0%
Goodwill	265,571	262,829	1%
Equity-accounted investees	407,214	423,873	-4%
Other financial assets	19,676	23,155	-15%
Deferred tax assets	27,893	27,637	1%
Other non-current assets	97,710	94,081	4%
Total non-current assets	2,017,152	2,054,851	-2%
Current assets			
Inventories	395,404	352,428	12%
Trade and other receivables	312,7		

USD'000	30 June 2023	31 Dec 2022	Var.
Non-current liabilities			
-			

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words

"anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.